Lilly(US:LLY) GLP1减重宝典·2026-01-20 09:12Core Viewpoint - The article discusses the effectiveness and safety of various FDA and EMA approved weight loss medications, emphasizing the superiority of tirzepatide and semaglutide in managing obesity and related health risks [4][5][6]. Research Methodology - A systematic review and meta-analysis were conducted, including randomized controlled trials from databases like Web of Science, PubMed, and Cochrane, focusing on weight loss medications approved for treating overweight or obesity [7]. Research Results - A total of 154 randomized controlled trials involving 112,515 participants were included. Tirzepatide showed the best weight loss results, followed by semaglutide. Tirzepatide also demonstrated the strongest antihypertensive effects and improved metabolic markers [9]. - Semaglutide and liraglutide were noted to reduce the risk of major adverse cardiovascular events (MACE), while naltrexone/bupropion increased blood pressure risk [9]. Tirzepatide Efficacy - In the SURMOUNT-1 study, tirzepatide led to significant weight loss in prediabetic patients, with reductions of 15.4% (5mg), 19.9% (10mg), and 22.9% (15mg) compared to a 2.1% reduction in the placebo group. It also reduced the risk of diabetes progression by 88% [11][14]. - The SURMOUNT-2 study confirmed that higher doses of tirzepatide resulted in an average weight loss of 15.7% (15.6kg) in type 2 diabetic patients [13]. Semaglutide Efficacy - The STEP series of studies indicated that semaglutide achieved an average weight loss of 15% in obese patients, significantly outperforming previous medications [17][19]. - In the STEP 1 study, semaglutide led to a 14.9% weight reduction, with over one-third of participants losing more than 20% of their weight [19]. - The STEP 4 study showed that continuous use of semaglutide resulted in an 18.2% weight loss, averaging 17.8kg [22]. Conclusion - The findings from these studies provide valuable insights into personalized weight management strategies, highlighting the effectiveness of GLP-1 receptor agonists like tirzepatide and semaglutide in treating obesity and improving metabolic health [6][9].